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Objectives: To investigate the association between anticholinergic drug burden (ADB), measured with
anticholinergic drug scales, and delirium and delirium severity.
Design: Systematic review.
Setting and Participants: All available studies.
Methods: A systematic literature search was performed in Medline, Embase, PsycINFO, Web of Science,
CINAHL, Cochrane library, and Google Scholar. Studies evaluating the association between ADB
(measured as a total score) and delirium or delirium severity, published in English, were eligible for
inclusion.
Results: Sixteen studies, including 148,756 persons, were included. Fifteen studies investigated delirium.
ADB was measured with the Anticholinergic Risk Scale (ARS, n ¼ 5), the Anticholinergic Cognitive Burden
Scale (ACB, n ¼ 6), the list of Chew (n ¼ 1), the Anticholinergic Drug Scale (ADS, n ¼ 5), a modified
version of the ARS (n ¼ 1), and a modified version of the ACB (n ¼ 1). A high ADB, measured with the
ARS, was associated with delirium (5/5). Also with the modified version of the ARS and ACB, an asso-
ciation was found between a high ADB and delirium during 3-month (1/1) and 1-year follow-up (1/1),
respectively. When ADB was assessed with other scales, the results were inconclusive, with only 1
positive association for the ACB (1/6) and ADS (1/5) each. The possible association between ADB and
delirium severity has also been investigated (ADS n ¼ 2, Summers Drug Risk Number n ¼ 1). One study
found an association between a high ADB, measured with the ADS, and an increase in severity of
delirium.
Conclusions and Implications: ADB assessed with the ARS is consistently associated with delirium. The
association found between the modified versions of the ARS and ACB and delirium needs confirmation.
When ADB was assessed with other scales, the findings were inconclusive. The current findings suggest
that the ARS might be a useful tool to identify patients at increased risk for delirium.
 2020 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Delirium is very common among older patients and is associated
with poor outcomes, such as functional and cognitive decline and
increased mortality.1 Despite the high prevalence and clinical impact,
this syndrome is still poorly understood. Knowledge about the un-
derlying pathophysiology and identification of modifiable risk factors
are of paramount interest.agencies in the public, com-
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C University Medical Center,
Netherlands.
ts).
te and Long-Term Care Medicine. TThe neurotransmitter acetylcholine is implicated in several pro-
cesses that are impaired during delirium, such as attention, sleep, and
memory, and this has led to the hypothesis that a cholinergic defi-
ciency might be involved in the pathogenesis of delirium.2,3 Drugs
with anticholinergic properties are commonly prescribed in older
persons, and the use of these drugs can cause some degree of
cholinergic deficiency by blocking the effects of acetylcholine.4
Therefore, use of anticholinergic drugs could be a risk factor for
delirium.
Previous studies have investigated the possible association be-
tween anticholinergic drugs and delirium, but the findings are con-
flicting.5,6 Discrepancies in the results might be caused by the
methods used to assess anticholinergic drug use, which differhis is an open access article under the CC BY license (http://creativecommons.org/
A. Egberts et al. / JAMDA 22 (2021) 65e7366substantially among studies.7 In some studies, anticholinergic drug
use is assessed with crude measures such as “exposed or not exposed”
or the total number of anticholinergic drugs taken. Other studies use
the anticholinergic drug burden (ADB), which takes into account the
specific anticholinergic load of the drugs used by a person. The ADB
can be calculatedwith anticholinergic drug scales and is defined as the
sum of scores assigned to the drugs. In the last decade, different
anticholinergic drug scales have been developed, but these scales
differ substantially from each other in number and ranking of drugs,
and the question rises whether the use of all these scales results in
comparable associations with delirium. Therefore, the aim of the
present review was to investigate the possible association between
ADB, measured with anticholinergic drug scales and delirium.
Methods
This review was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. The checklist is added as SupplementaryData (Appendix 1).
Data Sources and Search Strategy
A systematic literature search was performed in Medline Ovid,
Embase, PsycINFO, Web of Science, CINAHL, Cochrane library, and
Google Scholar covering the period up until January 31, 2020 using
relevant terms for anticholinergic drugs and delirium. The search
queries were developed with the assistance of an experienced
biomedical information specialist and can be found in the Supple-
mentary Data, Appendix 2. Reference lists of review articles and
included studies were manually screened to identify additional
eligible studies.
Eligibility Criteria
Studies that met each of the following criteria were eligible for
inclusion: (1) the association between ADB and delirium or delirium
severity was investigated; (2) ADB was measured with an anticho-
linergic drug scale and expressed as a total score; and (3) the study
was published in the English language. In case full text articles were
not available, the corresponding authors were contacted and when-
ever answers were not obtained despite reminders, articles were
excluded. Case studies, case series, review articles, commentaries,
letters, editorials, conference abstracts, and studies that used the Drug
Burden Index without stratification into the anticholinergic and
sedative components were excluded.
Study Screening and Selection
All references identified by the search queries were downloaded in
Endnote X9 (Clarivate Analytics, Philadelphia, PA) and duplicates were
removed. Three reviewers (A.E., R.M.G., and H.A.) independently
screened titles and abstracts for potentially eligible studies, and
assessed full-text articles against the eligibility criteria. Disagreements
at any stage were resolved through consensus.
Data Extraction
Data from all studies that met the inclusion criteria were inde-
pendently extracted by 2 authors (A.E. and F.M.R.) using a predefined
extraction table, including author, year of publication, study design,
population and setting, sample size, participant age and sex, number
of persons with delirium, methods of measuring ADB, tools used to
assess delirium and delirium severity, type of delirium (prevalent or
incident), information on the statistical analyses, and the results with
regard to the possible association between ADB and delirium (oddsratios, hazard ratios, relative risks, differences in proportions or
regression coefficients). When studies used multiple models to
investigate the association between ADB and delirium, the results of
themodel including themost covariates were extracted. Authors were
contacted when study details were missing and data were considered
unattainable if no answer was obtained despite several reminders.
Any uncertainties were resolved through discussion.
Quality Assessment
Two reviewers (A.E. and G.Z.) independently assessed the meth-
odological quality of the included studies using the Newcastle-Ottawa
Scale for cohort and case-control studies.8 The scale used for case-
control studies was additionally used for cross-sectional studies.9
The Newcastle-Ottawa Scale evaluates 3 aspects of the study meth-
odology: the selection of study groups (score range 0‒4), compara-
bility of the groups (score range 0‒2), and the quality of outcome/
exposure ascertainment (score range 0‒3). The total score ranges from
0 to 9 (highest quality). Disagreements were resolved through
discussion.
Data Synthesis
The association between ADB and delirium was investigated
separately for prevalent and incident delirium. To explore any varia-
tions in results across the studies and anticholinergic drug scales, the
results were additionally grouped based on the clinical settings where
the studies were performed, regardless of delirium type. Furthermore,
we planned to perform subgroup analyses to explore the influence of
potential confounding factors, such as dementia and severity of




The primary literature search resulted in 3085 records. After
exclusion of duplicates, 1960 records remained; of these, 1829 were
excluded based on titles and abstracts. In total, 131 records were
assessed for eligibility. Sixteen studies met the inclusion criteria and
were included in the final review. An overview of the study selection
process is presented in Figure 1.
Study Characteristics
The characteristics of the sixteen included studies are presented in
Table 1. There were 8 prospective cohort studies,10e13,16,17,21,26 5
retrospective cohort studies,14,18,23e25 1 nested case-control study,19
and 2 retrospective cross-sectional studies.20,22 A total of 148,756
personswere studied (sample size range90e118,750;mean¼9297.25;
median ¼ 420.5). Thirteen studies were conducted in the hospital
setting,10e14,17e22,25,26 of which 10 on a medical ward10,12e14,17e20,22,26
and 3 on a surgical ward,11,21,25 1 study was performed in nursing
homes,16 1 studywas performed in community-dwelling patientswith
dementia,23 and 1 study was performed in the general population.24
Delirium was assessed with the Diagnostic and Statistical Manual of
Mental Disorders (4th and 5th edition) criteria,19,20 the Confusion
Assessment Method,10,11,13,16,17,25,26 the Nursing Delirium Scale,25 the
Delirium Rating Scale,12 codes for delirium according to the Interna-
tional Classification of Diseases, 9th and 10th edition,18,23,24 the 4 ‘A’s
test,22 and a validated chart-based instrument developed by Inouye
et al15 for the identification of delirium14 anddocumented diagnoses of
delirium in discharge summaries.21 Delirium severity was assessed
with the Delirium Index10 and the Memorial Delirium Assessment
Records idenfied through database searching
(total n = 3084)
Embase (n = 1494), Medline (n = 386), Web of Science (n = 486),
Cochrane (n = 109), PsycINFO (n = 223), CINAHL (n = 186),
Google Scholar (n = 200)
Addional records idenfied 
through other sources
(n = 1)
Records aer duplicates removed (n = 1960)
Records screened on tle 
and abstract (n = 1960)
Full-text arcles assessed for 
eligibility (n = 131)
Records excluded, with reasons:
 No ACh drug scoring scale used (n = 19)
 Delirium (or severity) was not an outcome (n = 20)
 ACh drug burden score not calculated (n = 6)
 Not in the English language (n = 2)
 Conference abstract (n = 50)
 Review arcle (n = 11)
 DBI without straficaon (n = 1)
 Duplicate (n = 1)
 Duplicate analysis (n = 1)
 Design does not fit the research queson (n = 4)
Studies included in 
qualitave synthesis (n = 16)




















Fig. 1. PRISMA flow diagram of the study selection process.
A. Egberts et al. / JAMDA 22 (2021) 65e73 67Scale.12 ADB was measured with the Anticholinergic Risk Scale
(ARS),14,16e18,20 the Anticholinergic Cognitive Burden scale
(ACB),13,19e22,26 the list of Chew,20 the Anticholinergic Drug Scale
(ADS),10e12,17,19,25 a modified version of the ARS,24 and a modified
version of the ACB.23 Characteristics of these anticholinergic drug
scales are outlined in Table 2. Studies were performed in the United
States,12e14,18 the Netherlands,17,20 Italy,16,22 Canada,11,21 Korea,23,24
Norway,10 the United Kingdom,19 Germany,25 and Portugal.26Quality of the Studies
Details on the methodological quality of the included studies ac-
cording to the Newcastle-Ottawa Scale are provided as Supplementary
Data (Appendix 3). Quality scores ranged from 5 to 9 stars (median 8
stars). One study scored the maximum 4 stars for the study selection
criteria. Fourteen out of 16 studies scored the maximum 2 stars for the
comparability of the study groups, and 14 studies achieved the
maximum 3 stars for the outcome/exposure criteria.Anticholinergic Drug Burden and Delirium
The possible association between ADB and delirium was investi-
gated in 15 of the 16 studies.11e14,16e26 Four studies investigatedprevalent delirium,11,19,20,22 7 studies incident delirium,11e14,17,21,25 2
studies delirium at some point during the hospital stay (combination
of prevalent and incident delirium),18,26 1 study delirium during
3 months follow-up,24 and 2 studies delirium during 1-year follow-
up.16,23 The studies investigating incident delirium, delirium at some
point during the hospital stay, and delirium during follow-up are
combined in this review.Prevalent Delirium
Four studies reported on the possible association between ADB and
prevalent delirium (delirium on admission in 3 studies19,20,22 and
preoperative delirium in 1 study11). A total of 1993 persons were
studied (659 with delirium). Three studies were performed in acutely
ill patients admitted to the hospital19,20,22 and 1 study in patients
admitted with a hip fracture.11 In all 4 studies, themedian or mean age
was >80 years. Delirium was assessed with the Diagnostic and Sta-
tistical Manual of Mental Disorders (4th and 5th edition),19,20 the 4 ‘A’s
test,22 and the Confusion Assessment Method.11 ADB was assessed
with the ARS,20 the ACB,19,20,22 the ADS,11,19 and the list of Chew.20 The
study results are presented in Table 3. Only a moderate and high ADB,
measured with the ARS, was associated with delirium on admission.20
No associations were foundwith the other anticholinergic drug scales.
Table 1
Study Characteristics









Han et al, 200110 Prospective cohort Hospital Norway Acutely ill patients
with delirium age 65
278 83.4  7.3 38.8 278 CAM Delirium Index
Juliebø et al, 200911 Prospective cohort Hospital Canada Patients admitted




24.2 168 (46.2) CAM -
Fann et al, 201112 Prospective cohort Hospital USA Patients with malignancies
admitted for
myeloablative HSCT
90 41.5  9.9 48.9 45 (50) DRS MDAS
Campbell et al, 201113 Prospective cohort Hospital USA Patients with cognitive
impairment age 65
147 76.5  7.9 36.7 33 (22.4) CAM -





Landi et al, 201416 Prospective cohort Nursing homes Italy Nursing home
residents age 65
1490 83.5  8.0 28.5 Not defined NH-CAM -
Wolters et al, 201517 Prospective cohort Hospital The Netherlands Critically ill patients (ICU) 1112 60  16 60.4 535 (48) CAM-ICU -




52.6 362 (2.2) ICD-9 codes -
Moorey et al, 201619 Nested case control Hospital UK Acutely ill patients age
70
247 84.0  6.6 32.7 125 DSM-IV-TR -
Egberts et al, 201720 Retrospective
cross-sectional
Hospital The Netherlands Acutely ill patients age
65
905 81.0  7.0 48.3 215 (23.8) DSM-IV-TR
DSM-V
-
Hussain et al, 201821 Prospective cohort Hospital Canada Patients undergoing TAVI 90 83  6 61.1 7 (8.0) Clinical charts -
Pasina et al, 201922 Retrospective
cross-sectional
Hospital Italy Acutely ill patients age 65 477 83.9  6.5 41.9 151 (31.7) 4-‘A’s Test -







34.4 298 (4.0) ICD-10 codes -
Hwang et al, 201924 Retrospective cohort Population-based Korea Persons age 65 118,750 75.4  6.6 43.6 66 (0.05)y ICD-10 codes -
Mueller et al, 201925 Retrospective cohort Hospital Germany Cancer patients undergoing
surgery age 65
651 71.8  4.9 68.5 66 (10.1) CAM-ICU and Nu-DESC -
Rigor et al, 202026 Prospective cohort Hospital Portugal Acutely ill patients age 65 198 79.9  7.5 53.5 56 (28.3) Short-CAM -
CAM, Confusion Assessment Method; DRS, Delirium Rating Scale; DSM (TR), Diagnostic Statistical Manual of Mental Disorders (Text Revision); HSCT, hematopoietic stem-cell transplantation; ICD, International Classification of
Diseases; ICU, intensive care unit; IQR, interquartile range; MDAS, Memorial Delirium Assessment Scale; NH, nursing home; Nu-DESC, Nursing Delirium Scale; SD, standard deviation; TAVI, transcatheter aortic valve im-
plantation; UK, United Kingdom; USA, United States of America.
*Percentage not provided for case-control (matched) studies and studies that included only patients with delirium.
















Characteristics of the Anticholinergic Drug Scales
Anticholinergic Drug Scale (Publication Year) Basis of Scale Concept Number of Drugs with a Score >0 Grading System
ARS (2008)27 Pharmacological principles of 500 drugs and
expert opinion. Grading based on
anticholinergic potential. Scale attempts to
predict peripheral and central effects.
49 1-2-3
ACB (2008,28 updated in 2012)29 Literature review of drugs with anticholinergic
activity and expert opinion. Grading based on




ADS (2002)30 A pre-existing anticholinergic drug scale
(clinician-rated anticholinergic scale),
literature review and expert opinion. Grading
based on anticholinergic activity and the
potential to cause adverse effects.
117 1-2-3
Chew (2008)31 In vitro serum anticholinergic activity of 107
drugs commonly used by older adults.
39 0/þ, þ, þþ, þþþ
Modified ACB (2018)23 A pre-existing anticholinergic drug scale (ACB).
A literature search and expert opinion were
used to add and rank drugs available in Korea.
169 (9 drugs from the updated ACB scale were
excluded and 79 drugs were added)
1-2-3
Modified ARS (2019)24 A pre-existing anticholinergic drug scale (ARS).
A Delphi process involving 7 experts was used
to add and rank drugs available in Korea.
103 (6 drugs from the original ARS were
excluded and 60 drugs were added)
1-2-3
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Twelve studies reported on the possible association between ADB
and incident delirium.11e14,16e18,21,23e26 A total of 146,849 persons
were studied (1703 with delirium; in 1 study, the number of patients
with delirium was not defined16). Nine studies were performed in
patients admitted to the hospital (palliative inpatients,14 patients with
cognitive impairments,13 patients admitted to the Intensive Care
Unit,17 patients with a hip fracture undergoing surgery,11 patients with
Parkinson’s disease,18 patients undergoing transcatheter aortic valveTable 3
Study ResultsePrevalent Delirium
ACh Drug Scale Reference Drug Exposure Adjustments
ARS Egberts et al, 201720 Categories of ADB Age, sex, CC
of non-AC
ACB Moorey et al, 201619 Total ADB score
(continuous)
Age
Egberts et al, 201720 Categories of ADB Age, sex, CC
of non-AC
Pasina et al, 201922 Categories of ADB Age, sex, tum
dementia,
Nutritiona
ADS Juliebø et al, 200911 Categories of ADB None*
Moorey et al, 201619 Total ADB score
(continuous)
Age
Chew Egberts et al, 201720 Categories of ADB Age, sex, CC
of non-AC
ACh, anticholinergic; CCI, Charlson Comorbidity Index; CI, confidence interval; HR, haza
Values in bold are statistically significant (P < .05).
*ADB was not statistically significantly different between the groups and therefore noimplantation,21 patients with malignancies,12 cancer patients under-
going surgery,25 and acutely ill patients26), 1 study in nursing home
patients,16 1 study in community-dwelling patients with dementia,23
and 1 study in the general population.24 In 9 studies, the median or
mean age was >70 years,11,13,14,16,18,21,24e26 in 1 study 60.9% of the
patients were 75 years or older,23 in 1 study the mean age was
60 years,17 and in 1 study the mean agewas 41.5 years.12 Deliriumwas
assessed with the Confusion Assessment Method,11,13,16,17,25,26 the
Nursing Delirium Scale,25 the Delirium Rating Scale,12 International
Classification of Diseases, 9th and 10th edition codes for delirium,18,23,24Outcome Results OR/HR/RR/b(95% CI)
or Proportions with P Value
I, number
h drugs
Prevalent delirium Total ADB score 1-2:
OR 1.70 (1.16 e 2.49)
Total ADB score 3:
OR 1.83 (1.06 e 3.15)
Prevalent delirium OR ns
I, number
h drugs
Prevalent delirium Total ADB score 1-2:
OR 0.99 (0.67 e 1.46)
Total ADB score 3:




Prevalent delirium Total ADB score 1:
OR 0.93 (0.49 e 1.79)
Total ADB score 2:
OR: 1.01 (0.47 e 2.16)
Total ADB score 3:
OR 1.81 (0.74 e 4.47)
Total ADB score 4:
OR 2.19 (0.87 e 5.53)
Total ADB score 5:
OR 2.73 (0.85 e 8.77)




Prevalent delirium OR ns
I, number
h drugs
Prevalent delirium Total ADB score 0.5-1:
OR 1.00 (0.71 e 1.43)
Total ADB score 1.5:
OR 1.34 (0.85 e 2.11)
rds ratio; ns, not significant; OR, odds ratio; RR, risk ratio.
t included in the multivariate analysis.
Table 4
Study ResultseIncident Delirium
ACh Drug Scale Reference Drug Exposure Adjustments Outcome Results OR/HR/RR/b(95% CI)
or Proportions with P Value




Incident delirium OR: 1.4 (1.0e1.9)
Landi et al, 201416 Total ADB score at baseline
(continuous)
Age, sex, CIRS, CPS,
schizophrenia,
depression
Delirium during 1-y follow-
up
OR: 1.16 (1.02e1.32)
Wolters et al, 201517 Daily total ADB score
(continuous)
Age, sex, CCI, type of
admission, APACHE-IV,
use of mechanical
ventilation, length of ICU
stay until transition, SOFA
score without neurologic
component
Incident delirium OR: 1.12 (1.03e1.22)






Delirium at some point
during the during
hospital stayy
Total ADB score 1:
OR: 1.05 (0.69e1.61)
Total ADB score 2-3:
OR: 2.14 (1.46e3.15)
Total ADB score 4:
OR: 1.61 (1.08e2.40)
ACB Campbell et al, 201113 Total ADB score
(continuous)
Age, sex, African American
vs other, SPMSQ score,
CCI.
Incident delirium OR: 0.95 (0.80e1.13)
Hussain et al, 201821 Total ADB score
(continuous)
Age, history of stroke, atrial
fibrillation, diabetes,
general anesthesia
Postoperative delirium OR: 1.62 (0.81e3.24)
Rigor et al, 202026 Total ADB score
(continuous)






Delirium at some point
during the hospital stayy
OR: 1.65 (1.09e2.51)
ADS Juliebø et al, 200911 Categories of ADB on
admission




Fann et al, 201112 Total ADB score in the
previous 48 h






Wolters et al, 201517 Daily total ADB score
(continuous)
Age, sex, CCI, type of
admission, APACHE-IV,
use of mechanical
ventilation, length of ICU
stay until transition, SOFA
score without neurologic
component
Incident delirium OR: 1.05 (0.99e1.10)
Mueller et al, 201925 Total ADB score on
admission (continuous)
Age, ASA status, ICU stay Postoperative delirium OR: 1.50 (1.09e2.05)
Modified ARS Hwang et al, 201924 Average daily ADB score
during the first 3 mo
(categories)







ED visits for delirium
during 3 mo follow-up
Total ADB score 2:
HR: 2.05 (1.13e3.73)
Modified ACB Ah et al, 201923 Average daily ADB score








of ginkgo extract, high
sedative load
Delirium during 1-y follow-
up
Total ADB score >3:
HR: 1.52 (1.17e1.96)
ACh, anticholinergic; APACHE, Acute Physiology and Chronic Health Evaluation; ASA status, American Society of Anesthesiologists Physical Status; CCI, Charlson Comorbidity
Index; CI, confidence interval; CIRS, Cumulative Illness Rating Scale; CPS, Cognitive Performance Scale; ED, emergency department; ICU, intensive care unit; HR, hazards ratio;
ns, not significant; OR, odds ratio; RR, risk ratio; SOFA, Sequential Organ Failure Assessment; SPMSQ, Short Portable Mental Status Questionnaire
Values in bold are statistically significant (P < .05).
*ADB was not statistically significantly different between the groups and, therefore, not included in the multivariate analysis.
yIncludes prevalent and incident delirium.
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for the identification of delirium14 and documented diagnoses of
delirium in discharge summaries.21 ADB was assessed with the
ARS,14,16e18 the ACB,13,21,26 the ADS,11,12,17,25 a modified version of the
ARS,24 and a modified version of the ACB.23 The study results are
presented in Table 4. In all 4 studies using the ARS, an association was
found between ADB and incident delirium. A moderate and high ADB
as well as an increase in burden during the hospital stay, measured
with the ARS, was associated with an increased risk of developing
delirium. In addition, with the modified versions of the ARS and ACB,
an association was found between a high ADB and delirium during
follow-up. Conflicting results were found when the ADB was assessed
with the ACB or ADS.
Subgroup Analyses
The studies included in this review are performed in different
patient populations, which might influence the association. The out-
comes of the studies were therefore additionally grouped based on the
clinical setting (Supplementary Data, Appendix 4). Only in acutely ill
hospitalized patients was the association investigated more than 2
times (6 studies in total13,18e20,22,26): the ARS was used in 2
studies,18,20 the ACB in 5,13,19,20,22,26 and the ADS19 and Chew20 in 1.
Both studies that used the ARS found an association,18,20 and only 1
study that used the ACB did.26
In addition, the included studies used awide range of variables in the
multivariatemodels.Dementia and severityof acute illnessmight have a
large impact on the association between ADB and delirium.3 Only 2
studies adjusted for dementia22,26 and 3 for severity of acute illness as
defined by the Acute Physiology and Chronic Health Evaluation
(APACHE) score and the American Society of Anesthesiologists Physical
(ASA) status.14,17,25 Because of the small number of studies adjusting for
these variables, no subgroup analyses could be performed.
Anticholinergic Drug Burden and Delirium Severity
Two studies reported on the possible association between ADB and
delirium severity.10,12 A total of 368 persons were studied (323 with
delirium). One study was performed in acutely ill patients admitted to
the hospital10 and 1 study in patients with malignancies.12 Mean ages
in these studies were 84.3 years and 41.5 years, respectively. Delirium
was diagnosed with the Confusion Assessment Method10 and the
Delirium Rating Scale.12 The study results can be found in the Sup-
plementary Data, Appendix 5. Both studies used the ADS and 1 study10
found an association between an increase in ADB and an increase in
delirium severity.
Discussion
The findings of this systematic review demonstrate consistent
evidence that ADBmeasured with the ARS is associated with delirium.
In addition, with a modified version of the ARS and ACB an association
was found between high ADB and delirium. The findings were con-
flicting when ADB was assessed with other scales, with more negative
than positive studies.
This systematic review has evaluated the association between
anticholinergic drugs and delirium in more depth than previous re-
views.5,6 In the present review, we specifically included studies in
which the ADB score was calculated with a scale and this has highly
increased the ability to compare the findings. Previous reviews have
reported conflicting findings and these discrepancies can be caused by
the fact that the included studies were quite heterogeneous in their
quantification of the anticholinergic load. Moreover, the review ofWelsh et al included only other systematic reviews about ADB tools
and was not designed to investigate the association between anti-
cholinergic drugs and delirium.32
The 16 studies included in the present review have used 6 different
anticholinergic drug scales (ie, the ARS, ACB, ADS, the list of Chew, a
modified version of the ARS, and a modified version of the ACB), and
only the ARS was consistently associated with delirium (5 out of 5
studies found a positive association). Also, in the 2 studies that used a
modified version of the ARS and ACB, an association was found be-
tween a high ADB and delirium during the 3-month24 and 1-year
follow-up,23 respectively. The modified version of the ARS includes
60 more drugs,24 and the modified version of the ACB includes 79
more drugs23 than the original ARS27 and ACB scale.29 Moreover, in
both studies, the authors also took into account the daily drug dose
and, therefore, the findings cannot be compared with findings found
with the original scales.When ADBwas assessedwith other scales, the
results were inconclusive, with only 1 positive association for the
ACB26 (1 out of 6 studies) and 1 for the ADS25 (1 out of 5 studies). An
explanation for the discrepancies in findings might be the large dif-
ferences in the total number and ranking of drugs between the
available anticholinergic drug scales as well as the different methods
used to develop the scales. A previous study has evaluated the
agreement between the ARS, ACB, ADS, and the anticholinergic sub-
scale of the Drug Burden Index for measuring ADB, and found a poor
agreement between the 4 scales. Only the ACB and ADS showed a good
agreement,33 and these findings were confirmed in another study.34
Previous systematic reviews have already highlighted that the asso-
ciation between anticholinergic drug scales and outcomes, such as
mortality and physical function, can be different depending on which
scale is used.35e37 Therefore, the large differences in themeasurement
of the ADB among the available anticholinergic drug scales can also
have a high impact on finding an association with delirium.
In addition, the ARS attempts to predict both peripheral and cen-
tral effects,27 in contrast to the ACB in which the grading of drugs is
based on the potential to cause cognitive effects.28 It might be possible
that in delirium not only central, but also peripheral anticholinergic
effects may play a role. Blurred vision, urinary retention, and con-
stipation, known peripheral adverse effects of anticholinergic drugs,4
are risk factors for delirium38 and might explain why the ARS was
associated with delirium. However, because the individual studies did
not report on adverse effects, this remains speculative.
Furthermore, it might be possible that the differences in findings
among the anticholinergic drug scales are caused by the variety in
patient populations and the diversity in variables for which has been
adjusted in multivariate models. Unfortunately, no conclusions can be
drawn because some patient populations have only been studied
once. Only in acutely ill older patients has the association between
ADB and delirium been investigated several times.13,18e20,22,26 Five
studies used the ACB (with almost comparable mean age and delirium
prevalence),13,19,20,22,26 and only 1 study found an association.26
Moreover, the included studies did not adjust for the same con-
founding factors. Factors that might influence the association, such as
dementia and baseline severity of illness,3 were not always included in
the analyses and, therefore, no conclusions can be drawn for the effect
of possible confounders.
Based on the findings of the present review, it can be concluded
that the ARS could be a suitable instrument to identify patients at
increased risk of delirium. Previous studies have shown that medi-
cation reviews can be effective in reducing ADB scores (based on the
ARS) in persons age 65 years and older.39,40 Therefore, it would be
interesting to investigate whether regular medication reviews with
the ARS as an additional tool, in both the community and hospital
setting, will reduce delirium.
A. Egberts et al. / JAMDA 22 (2021) 65e7372Limitations and Strengths
This systematic review has some limitations. First, our search was
limited to articles published in the English language. As far as we are
aware, there is 1 study published in Spanish in which the association
between the ARS, ACB, and ADS and delirium was investigated in
patients admitted to a geriatric ward of a hospital.41 The results are in
linewith our findings: a significant associationwas found between the
ARS and incident delirium and no association was found with the
other anticholinergic drug scales. Second, one might speculate that
publication bias could have played a role, considering that 50 con-
ference abstracts were excluded. Of these 50 abstracts, 8 abstracts
explicitly described that they have investigated the association be-
tween ADB, measured with a scale, and delirium. Two of these ab-
stracts are included as full-text studies in the present review. Of the
remaining abstracts, 3 have used the ARS, of which 2 have found an
association and 1 not; 4 abstracts have used the ACB and none have
found an association; and the ADS was used in 1, and also this abstract
found no association. These findings are in line with the results of the
present review, and therefore, we think that publication bias has not
influenced the results. Third, there was considerable heterogeneity
among the studies. However, considering that the evidence for the
ARS is consistent among the studies despite the different settings and
populations, we do not believe that this has influenced our findings.
Fourth, the studies included in this review used the ARS, ACB, ADS, and
the list of Chew. Although these are the most frequently used scales in
research, other scales exist and it is not known whether these scales
are associated with delirium. Moreover, the list of Chew and the
modified versions of the ACB and ARS were only used in 1 study
each20,23,24; therefore, confirmation of the findings is warranted. Fifth,
this review identified only 2 studies investigating the possible asso-
ciation between ADB and the severity of delirium,10,12 which hampers
the ability to draw conclusions. More studies in this field are needed.
Major strengths of this review are the comprehensive search,
which was performed in multiple databases, and the inclusion, which
was limited to studies in which the ADB score was calculated.Conclusions and Implications
The findings of this systematic review demonstrate consistent
evidence that ADBmeasured with the ARS is associated with delirium.
Also, with the modified versions of the ARS and ACB, an association
was found between high ADB and delirium, but these findings need
confirmation. The current findings suggest that the ARS might be a
useful tool to identify persons at increased risk for delirium. Future
studies are needed to investigate whether regular medication reviews
with the ARS in both the community and hospital settings will reduce
delirium.Acknowledgments
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Appendix 1. PRISMA Checklist
Section/Topic # Checklist Item Reported on page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background; objectives;
data sources; study eligibility criteria, participants, and interventions; study
appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.
2-3
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 4
Objectives 4 Provide an explicit statement of questions being addressed with reference to
participants, interventions, comparisons, outcomes, and study design (PICOS).
4
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (eg, Web
address), and, if available, provide registration information including
registration number.
Not available
Eligibility criteria 6 Specify study characteristics (eg, PICOS, length of follow-up) and report
characteristics (eg, years considered, language, publication status) used as
criteria for eligibility, giving rationale.
5
Information sources 7 Describe all information sources (eg, databases with dates of coverage, contact
with study authors to identify additional studies) in the search and date last
searched.
5
Search 8 Present full electronic search strategy for at least one database, including any
limits used, such that it could be repeated.
Appendix 2
Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in
systematic review, and, if applicable, included in the meta-analysis).
6
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms,
independently, in duplicate) and any processes for obtaining and confirming
data from investigators.
6
Data items 11 List and define all variables for which data were sought (eg, PICOS, funding
sources) and any assumptions and simplifications made.
6
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including
specification of whether this was done at the study or outcome level), and how
this information is to be used in any data synthesis.
6-7
Summary measures 13 State the principal summary measures (eg, risk ratio, difference in means). 6
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done,
including measures of consistency (eg, I2) for each meta-analysis.
Not applicable
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence
(eg, publication bias, selective reporting within studies).
Not applicable
Additional analyses 16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses,
meta-regression), if done, indicating which were pre-specified.
7
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the
review, with reasons for exclusions at each stage, ideally with a flow diagram.
8, Figure 1
Study characteristics 18 For each study, present characteristics for which data were extracted (eg, study
size, PICOS, follow-up period) and provide the citations.
8-9, Table 1
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level
assessment (see item 12).
9, appendix 3
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a)
simple summary data for each intervention group (b) effect estimates and
confidence intervals, ideally with a forest plot.
9-12, Tables 3 and 4, appendix 4-5
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and
measures of consistency.
Not applicable
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Not applicable
Additional analysis 23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses,
meta-regression [see Item 16]).
11-12
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main
outcome; consider their relevance to key groups (eg, healthcare providers,
users, and policy makers).
13-15
Limitations 25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-
level (eg, incomplete retrieval of identified research, reporting bias).
15-16
Conclusions 26 Provide a general interpretation of the results in the context of other evidence,
and implications for future research.
16
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (eg,
supply of data); role of funders for the systematic review.
Title page
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Appendix 2. Search Strategy
embase.com
(’cholinergic receptor blocking agent’/mj OR ’anticholinergic effect’/de OR ’anticholinergic syndrome’/de OR (((cholinerg* OR acetylcholin*-
receptor* OR AChR OR parasympath*) NEAR/3 (block* OR anti* OR inhibitor*)) OR anticholinergic* OR cholinolytic* OR para-
sympatholytic*):kw,ab,ti) AND (’delirium’/exp OR confusion/exp OR ’delusion’/de OR ’delusional disorder’/de OR ’somatic delusion’/de OR (delier
OR delir* OR delusion* OR confusion*):kw,ab,ti) NOT (’case report’/de OR ((case NEAR/3 report)):kw,ab,ti) AND [english]/lim
Medline Ovid
(Cholinergic Antagonists/ OR Anticholinergic Syndrome/ OR (((cholinerg* OR acetylcholin*-receptor* OR AChROR parasympath*) ADJ3 (block*
OR anti* OR inhibitor*)) OR anticholinergic* OR cholinolytic* OR parasympatholytic*).kw,ab,ti.) AND (exp confusion/ OR Delusions/ OR (delier OR
delir* OR delusion* OR confusion*).kw,ab,ti.) NOT (case report/ OR ((case ADJ3 report)).kw,ab,ti.) AND english.la.
Web of science
TS¼(((((cholinerg* OR acetylcholin*-receptor* OR AChR OR parasympath*) NEAR/2 (block* OR anti* OR inhibitor*)) OR anticholinergic* OR
cholinolytic* OR parasympatholytic*)) AND ((delier OR delir* OR delusion* OR confusion*)) NOT (((case NEAR/2 report)))) AND LA¼(english)
Cochrane CENTRAL
((((cholinerg* OR acetylcholin* NEXT/1 receptor* OR AChR OR parasympath*) NEAR/3 (block* OR anti* OR inhibitor*)) OR anticholinergic* OR
cholinolytic* OR parasympatholytic*):kw,ab,ti) AND ((delier OR delir* OR delusion* OR confusion*):kw,ab,ti) NOT (((case NEAR/3
report)):kw,ab,ti)
PsycINFO Ovid
(Cholinergic Blocking Drugs/ OR (((cholinerg* OR acetylcholin*-receptor* OR AChR OR parasympath*) ADJ3 (block* OR anti* OR inhibitor*)) OR
anticholinergic* OR cholinolytic* OR parasympatholytic*).ab,ti.) AND (Delirium/ OR Delusions/ OR (delier OR delir* OR delusion* OR con-
fusion*).ab,ti.) NOT (case report/ OR ((case ADJ3 report)).ab,ti.) AND english.la.
CINAHL EBSCOhost
(MH Cholinergic Antagonists OR TI (((cholinerg* OR acetylcholin*-receptor* OR AChROR parasympath*) N2 (block* OR anti* OR inhibitor*)) OR
anticholinergic* OR cholinolytic* OR parasympatholytic*) OR AB (((cholinerg* OR acetylcholin*-receptor* OR AChR OR parasympath*) N2 (block*
OR anti* OR inhibitor*)) OR anticholinergic* OR cholinolytic* OR parasympatholytic*)) AND (MH confusionþ OR TI (delier OR delir* OR delusion*
OR confusion*) OR AB (delier OR delir* OR delusion* OR confusion*)) NOT (MH Case Studies OR TI ((case N2 report)) OR AB ((case N2 report))) AND
LA english
Google scholar
“cholinergicjacetylcholine receptor blockerjinhibitor”:janticholinergicjcholinolyticjparasympatholytic deliriumjdelusionjconfusion
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Han et al, 200110 0 1 1 0 2 1 1 0 6
Juliebø et al, 200911 0 1 1 1 2 1 1 1 8
Fann et al, 201112 0 1 1 1 1 1 1 1 7
Campbell et al, 201113 0 1 1 1 2 1 1 1 8
Zimmerman et al, 201414 0 1 1 1 2 1 1 1 8
Landi et al, 201416 1 1 1 1 2 1 1 1 9
Wolters et al, 201517 0 1 1 1 2 1 1 1 8
Crispo et al, 201618 0 1 0 0 2 1 1 1 6
Hussain et al, 201821 0 1 0 0 2 0 1 1 5
Ah et al, 201923 1 1 1 0 2 1 1 1 8
Hwang et al, 201924 1 1 1 0 2 1 1 1 8
Mueller et al, 201925 0 1 1 1 2 1 1 1 8
Rigor et al, 202026 0 1 1 0 2 1 1 1 7















Moorey et al, 201619 1 1 0 1 1 1 1 1 7
Cross-sectional
Egberts et al, 201720 1 1 0 1 2 1 1 1 8
Pasina et al, 201922 1 1 0 1 2 1 1 1 8
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Supplementary Table A1
Study Results Stratified on Study Population
Ach Drug Scale Reference Sample Size, n Age in y, Mean  SD Delirium, n (%)* Results OR, HR or Proportions
with P Value
Acutely ill
ARS Egberts et al,20 905 81.0  7.0 215 (23.8) Total ADB score 1-2:
OR 1.70 (1.16e2.49)
Total ADB score 3:
OR 1.83 (1.06e3.15)
Crispo et al.18 16,302 Unknown,
82.4% 70 years
362 (2.2) Total ADB score 1:
OR 1.05 (0.69e1.61)
Total ADB score 2-3:
OR 2.14 (1.46e3.15)
Total ADB score 4:
OR 1.61 (1.08e2.40)
ACB Egberts et al.20 905 81.0  7.0 215 (23.8) Total ADB score 1-2:
OR 0.99 (0.67e1.46)
Total ADB score 3:
OR 1.39 (0.89e2.18)
Moorey et al.19 247 84.0  6.6 125 OR ns
Pasina et al.22 477 83.9  6.5 151 (31.7) Total ADB score 1:
OR 0.93 (0.49e1.79)
Total ADB score 2:
OR 1.01 (0.47e2.16)
Total ADB score 3:
OR 1.81 (0.74e4.47)
Total ADB score 4:
OR 2.19 (0.87e5.53)
Total ADB score 5:
OR 2.73 (0.85e8.77)
Rigor et al.26 198 79.9  7.5 56 (28.3) OR 1.65 (1.09e2.51)
Campbell et al.13 147 76.5  7.9 33 (22.4) OR 0.95 (0.80e1.13)
ADS Moorey et al.19 247 84.0  6.6 125 OR ns
Chew Egberts et al.20 905 81.0  7.0 215 (23.8) Total ADB score 0.5-1:
OR 1.00 (0.71e1.43)
Total ADB score 1.5:
OR 1.34 (0.85e2.11)
Critically ill
ARS Wolters et al.17 1112 60  16 535 (48) OR 1.12 (1.03e1.22)
ADS Wolters et al.17 1112 60  16 535 (48) OR 1.05 (0.99e1.10)
Surgical
ACB Hussain et al.21 90 83  6 7 (8.0) OR 1.62 (0.81e3.24)
ADS Juliebø et al.11 364 Unknown, median (IQR):
84 (79-88)
168 (46.2) Preoperative delirium:









Cancer and/or cancer-related surgery
ADS Fann et al.12 90 41.5  9.9 45 (50) HR: ns
Mueller et al.25 651 71.8  4.9 66 (10.1) OR 1.50 (1.09e2.05)
Palliative
ARS Zimmerman et al.14 217 72.9  12.8 67 (30.9) OR 1.4 (1.0e1.9)
Community
Modified ARS Hwang et al.24 1,18,750 75.4  6.6 66 (0.05) Total ADB score 2:
HR: 2.05 (1.13e3.73)
Modified ACB Ah et al.23 7438 Unknown,
60.9% 75 years
298 (4.0) Total ADB score >3:
HR: 1.52 (1.17e1.96)
Nursing home
ARS Landi et al.16 1490 83.5  8.0 Not defined OR 1.16 (1.02e1.32)
Values in bold are statistically significant (P < .05).
ACh, anticholinergic; CI, confidence interval; HR, hazards ratio; ns, not significant; OR, odds ratio.
*Percentage not provided for case-control (matched) studies and studies that included only patients with delirium.
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Supplementary Table A2
Study ResultseDelirium Severity
ACh Drug Scale Reference Drug Exposure Type of Analysis Results OR/HR/RR/b (95% CI)
ADS/clinician-rated
ACh scale
Han et al, 200110 Daily total ADB score Multivariate b [ 0.20 (0.03e0.38), P ¼ .02
Fann et al, 201112 Total ADB score in the previous 48 h Multivariate b ¼ 0.03 (0.06 to 0.11), P ¼ .52
Summers Drug Risk Number Han et al, 200110 Daily total ADB score Multivariate b ¼ 0.07 (0.07 to 0.21), P ¼ .35
ACh, anticholinergic; CI, confidence interval; HR, hazards ratio; OR, odds ratio; RR, risk ratio.
Values in bold are statistically significant (P < .05).
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